264 results
P
adults in England
I/C
benzodiazepine or Z-drug (BZRA) deprescribing, gradual tapering alone
O
successful discontinuation in the short and long term, and withdrawal symptoms
P
BPH patients with DU
I/C
transurethral surgical treatment, pharmacological treatment
O
improvements in Q
P
Lewy body disease (LBD), Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), healthy elderly individuals
I/C
orexin-A levels in cerebrospinal fluid (CSF), patients with LBD vs. patients with AD, patients with LBD vs. patients with FTLD, LBD patients with excessive daytime sleepiness (EDS) vs. healthy elderly individuals
O
mean orexin-A CSF levels, standard mean difference (SMD), 95% confidence interval (CI), Z-score, P-value
P
patients with non-acute lung injury/acute respiratory distress syndrome (non-ALI/ARDS) under general anesthesia mechanical ventilation in the intensive care unit (ICU)
I/C
continuous high positive end-expiratory pressure (PEEP) ventilation, control group with low PEEP
O
hospital mortality or 28-day mortality, partial oxygen pressure, incidence of ARDS, atelectasis, and lung infections
P
social anxiety
I/C
post-event rumination, treatments specifically targeting post-event rumination
O
social anxiety symptomatology
P
patients with staged implant-based breast reconstruction (IBR)
I/C
fat grafting during second-stage expander/implant exchange, third-stage fat grafting
O
BREAST-Q satisfaction with outcome scores
P
prolactinoma, hyperprolactinemia
I/C
prolactin excess, control group
O
BMD Z-scores, bone mineral density, bone mineral content, fragility fractures
P
insomnia
I/C
orexin receptor antagonists (ORAs), benzodiazepine-like drugs (Z-drugs), melatonin receptor agonists (MRAs), placebo
O
sleep latency (SL), awake time after sleep onset (WASO), total sleep time (TST), sleep efficiency (SE), sleep quality (SQ), adverse events (AED)
P
patients with Diabetes Mellitus (DM)
I/C
ancient grains, no intervention
O
lipidic profile